Comparative Pharmacology
Head-to-head clinical analysis: ALBENDAZOLE versus ALBENZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENDAZOLE versus ALBENZA.
ALBENDAZOLE vs ALBENZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
None Documented
None Documented
Clinical Note
moderateAlbendazole + Digoxin
"Albendazole may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlbendazole + Digitoxin
"Albendazole may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlbendazole + Deslanoside
"Albendazole may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAlbendazole + Acetyldigitoxin
"Albendazole may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
Category D/X
Category C
Anthelmintic
Anthelmintic